A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects | NCT02429102 | Trialant
CompletedInterventionalPhase 1Updated Dec 22, 2025
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects
ClinicalTrials.gov ID
NCT02429102
Lead Sponsor
Tanabe Pharma CorporationINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
135Actual
Last Update Posted
Dec 22, 2025Actual
Start Date
Apr 2015
Primary Completion Date
Nov 2015Actual
Completion Date
Nov 2015Actual
Brief Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of MT-8554 in healthy Caucasian subjects.
Healthy
MT-8554
Placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
Yes
Eligibility Criteria
Inclusion Criteria:
Healthy and free from clinically significant illness or disease
Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65
A body weight of ≥60 kg male and ≥50 kg female
Exclusion Criteria:
Participation in more than three clinical studies involving administration of an Investigational Medicinal Product (IMP) in the previous year, or any study within 12 weeks.
Clinically significant endocrine, thyroid, hepatic, respiratory, gastro-intestinal, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder.
Clinically relevant abnormal medical history, physical findings or laboratory values